Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/medlaw/fwab028 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The prevalence of fibromyalgia in adults at Al-Karak Jordan: a cross-sectional study.
Ann Med Surg (Lond)
March 2024
School of Medicine, Mutah University, Al-Karak, Jordan, Red Cresent Hospital, Amman, Jordan.
Introduction: Fibromyalgia is a chronic and intricate musculoskeletal disorder characterized by widespread pain, fatigue, and tenderness in specific anatomical regions. Although its prevalence varies among populations, understanding the prevalence in different geographical areas is crucial for healthcare planning. This cross-sectional study aims to determine the prevalence of fibromyalgia in adults residing in Al-Karak, Jordan.
View Article and Find Full Text PDFTherapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignancies.
Cancer Cell
December 2023
Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK; The Christie NHS Foundation Trust, Manchester M20 4BX, UK. Electronic address:
CCS1477 (inobrodib) is a potent, selective EP300/CBP bromodomain inhibitor which induces cell-cycle arrest and differentiation in hematologic malignancy model systems. In myeloid leukemia cells, it promotes rapid eviction of EP300/CBP from an enhancer subset marked by strong MYB occupancy and high H3K27 acetylation, with downregulation of the subordinate oncogenic network and redistribution to sites close to differentiation genes. In myeloma cells, CCS1477 induces eviction of EP300/CBP from FGFR3, the target of the common (4; 14) translocation, with redistribution away from IRF4-occupied sites to TCF3/E2A-occupied sites.
View Article and Find Full Text PDFHMG20B stabilizes association of LSD1 with GFI1 on chromatin to confer transcription repression and leukemia cell differentiation block.
Oncogene
October 2022
Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, The University of Manchester, Manchester Cancer Research Centre Building, 555 Wilmslow Road, Manchester, M20 4GJ, UK.
Pharmacologic inhibition of LSD1 induces molecular and morphologic differentiation of blast cells in acute myeloid leukemia (AML) patients harboring MLL gene translocations. In addition to its demethylase activity, LSD1 has a critical scaffolding function at genomic sites occupied by the SNAG domain transcription repressor GFI1. Importantly, inhibitors block both enzymatic and scaffolding activities, in the latter case by disrupting the protein:protein interaction of GFI1 with LSD1.
View Article and Find Full Text PDFBlast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
BMC Cancer
October 2021
Leukaemia Biology Laboratory, Cancer Research UK Manchester Institute, Oglesby Cancer Research Building, The University of Manchester, 555 Wilmslow Road, Manchester, M20 4GJ, UK.
Background: Disease relapse remains common following treatment of acute myeloid leukemia (AML) and is due to chemoresistance of leukemia cells with disease repopulating potential. To date, attempts to define the characteristics of in vivo resistant blasts have focused on comparisons between leukemic cells at presentation and relapse. However, further treatment responses are often seen following relapse, suggesting that most blasts remain chemosensitive.
View Article and Find Full Text PDFBasma v Manchester University Hospitals NHS Foundation Trust: The Scrutiny of a Clinical Judgement.
Med Law Rev
December 2021
Department of Surgery, The Leeds Teaching Hospitals NHS Trust, Leeds LS9 7TF, UK.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!